Breast Cancer Coverage From Every Angle

Use of Dexamethasone Oral Solution in Patients Receiving Treatment for Breast Cancer

For patients receiving everolimus and exemestane therapy for breast cancer, the prophylactic use of a dexamethasone oral solution substantially reduced the incidence and severity of stomatitis, according to a study by Rugo et al in The Lancet Oncology. The investigators suggest this dexamethasone mouthwash could be a new standard of oral care for these patients.

A total of 92 women aged 18 years and older with a postmenopausal status who had histologically or cytologically confirmed metastatic hormone receptor–positive, HER2-negative breast cancer were enrolled on this U.S.-based, multicenter, single-arm phase II prevention study. By 8 weeks, the incidence of grade 2 or worse stomatitis was 2% (2 of the 85 evaluable patients, 95% confidence interval [CI]: 0.29–8.24), vs 33% (159 of 482 patients, 95% CI: 28.8–37.4) for the duration of the BOLERO-2 study.

Overall, about 90% of study patients had at least one adverse event, with the most reported grade 3 and 4 adverse events in the safety set being hyperglycemia (8%), rash (4%), and dyspnea (3%). A total of 12 of the 92 patients (13%) had adverse events suspected to be related to treatment, which led to discontinuation of everolimus and exemestane; the most common were rash, hyperglycemia, and stomatitis, which each affected 2% of patients.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.